Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

0.9599 +0.0299 (+3.22%)
Streaming Delayed Price Updated: 2:35 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Cor

< Previous 1 2 3 4 5 Next >
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
From CytoSorbents; Converge Biotech
Via GlobeNewswire
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
From CytoSorbents
Via GlobeNewswire
Analyst Scoreboard: 5 Ratings For CytoSorbents
Via Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
Via Benzinga
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
Recap: CytoSorbents Q4 Earnings
Via Benzinga
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
From CytoSorbents
Via GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
From CytoSorbents
Via GlobeNewswire
Why CytoSorbents (CTSO) Stock Is Trading Higher
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group. 
Via Benzinga
CytoSorbents Secures $20 Million Credit Facility
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
From CytoSorbents
Via GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Meets EPS, Beats Revenue for Q1 2024
CTSO stock results show that CytoSorbents met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
CytoSorbents Reports First Quarter 2024 Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.